Key Insights

Highlights

Success Rate

74% trial completion

Published Results

286 trials with published results (20%)

Research Maturity

527 completed trials (36% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

12.7%

186 terminated out of 1464 trials

Success Rate

73.9%

-12.6% vs benchmark

Late-Stage Pipeline

8%

123 trials in Phase 3/4

Results Transparency

54%

286 of 527 completed with results

Key Signals

286 with results74% success186 terminated

Data Visualizations

Phase Distribution

1,278Total
Not Applicable (108)
Early P 1 (23)
P 1 (586)
P 2 (438)
P 3 (106)
P 4 (17)

Trial Status

Completed527
Recruiting290
Unknown193
Terminated186
Active Not Recruiting121
Not Yet Recruiting65

Trial Success Rate

73.9%

Benchmark: 86.5%

Based on 527 completed trials

Clinical Trials (1464)

Showing 20 of 20 trials
NCT06021600Phase 1Terminated

A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

NCT07737769Phase 1Not Yet RecruitingPrimary

Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT06529731Phase 2RecruitingPrimary

Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

NCT07548710Phase 2RecruitingPrimary

Study of SA+X in the Treatment of Newly Diagnosed AML

NCT05457556Phase 3Active Not Recruiting

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

NCT05564390Phase 2RecruitingPrimary

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT07735208Phase 2Not Yet RecruitingPrimary

Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia

NCT04293562Phase 3RecruitingPrimary

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

NCT06034470Phase 1Active Not RecruitingPrimary

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

NCT06616636Phase 1Recruiting

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

NCT07020533Phase 1Recruiting

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

NCT05955261Phase 2SuspendedPrimary

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

NCT04093570Phase 2Enrolling By InvitationPrimary

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

NCT07392970Phase 2RecruitingPrimary

Motixafortide for MRD Sensitization in AML

NCT06152809Phase 1RecruitingPrimary

CIML NK Cells With Venetoclax for AML

NCT05189639RecruitingPrimary

A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia

NCT07346105Unknown

Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies

NCT03934372Phase 1RecruitingPrimary

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

NCT03374332Phase 1CompletedPrimary

Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

NCT03836209Phase 2CompletedPrimary

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

Scroll to load more

Research Network

Activity Timeline